Aurobindo Pharma Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Mid Cap

The new injectable facility of Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the company), situated at Parawada Mandal, Anakapalli district, Andhra Pradesh, has recently started the commercial operations.

The United States Food and Drug Administration (USFDA) inspected the facility from 28 March 2024 to 5 April 2024.

The inspection closed with three observations. The observations are procedural in nature and will be responded to within the stipulated time, the company stated in the press release.

On 6 April 2024, the company informed that an accident occurred near Vacuum Tray Dryer (VTD) area at Unit 6 of Apitoria Pharma (wholly owned subsidiary of the company), situated at Parawada, Anakapalli district, Andhra Pradesh. The firm said that there was one casualty due to the accident.

Further, the company added the unit continues its normal operations.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The drug maker reported 90.58% jump in consolidated net profit to Rs 936.29 crore on 13.82% rise in revenue from operations to Rs 7,271.23 crore in Q3 FY24 over Q3 FY23.

The scrip shed 0.19% to end at Rs 1,121 on the BSE.

Powered by Capital Market - Live News

Aurobindo Pharma announced that on 06 April 2024 at around 11:30 PM (IST), an accident occurred near Vacuum Tray Dryer (VTD) area at Unit 6 of Apitoria Pharma, situated at Parawada, Anakapalli District, Andhra Pradesh. Unfortunately, there was one casualty due to the accident.

The unit continues its normal operations.

Powered by Capital Market - Live News

Aurobindo Pharma has appointed T. Vijaya Kumar as President – R&D (Specialty Drug Delivery) effective 05 April 2024. Accordingly, T. Vijaya Kumar will be part of the Senior Management team of the Company.

Powered by Capital Market - Live News

The key benchmarks indices traded with limited losses in mid-morning trade. The Nifty traded below the 21,800 level. Pharma shares extended losses for the second consecutive trading sessions.

At 11:27 IST, the barometer index, the S&P BSE Sensex, was down 152.69 points or 0.21% to 71,859.36. The Nifty 50 index shed 46.15 points or 0.21% to 21,771.30.

In the broader market, the S&P BSE Mid-Cap index shed 0.52% and the S&P BSE Small-Cap index declined 0.60%.

The market breadth was weak. On the BSE, 1,307 shares rose and 2,244 shares fell. A total of 132 shares were unchanged.

Economy:

The provisional figures of Gross collection of Direct Taxes (before adjusting for refunds) for the Financial Year 2023-24 stand at Rs 22,27,067 crore compared to Rs 18,75,535 crore in the corresponding period of the preceding financial year, showing a growth of 18.74% over the collections of FY 2022-23.

The Gross collection of Rs 22,27,067 crore includes Corporation Tax (CIT) at Rs 10,98,183 crore and Personal Income Tax (PIT) including Securities Transaction Tax (STT) at Rs 11,25,228 crore. Minor head wise collection comprises Advance Tax of Rs 9,11,534 crore; Tax Deducted at Source of Rs 10,44,511 crore; Self-Assessment Tax of Rs. 1,73,296 crore; Regular Assessment Tax of Rs 73,548 crore; and Tax under other minor heads of Rs 24,177 crore.

Buzzing Index:

The Nifty Pharma index shed 0.89% 18,242.15. The index slipped 3.04% in the past two trading sessions.

Laurus Labs (down 3%), Gland Pharma (down 2.61%), Abbott India (down 2.07%), Zydus Lifesciences (down 1.76%), Alkem Laboratories (down 1.72%), Granules India (down 1.39%), Sun Pharmaceuticals Industries (down 1.18%), Dr Reddys Laboratories (down 0.98%), Sanofi India (down 0.9%) and Divis Laboratories (down 0.77%) declined.

On the other hand, Glaxosmithkline Pharmaceuticals (up 2.05%), Aurobindo Pharma (up 1.14%) and Biocon (up 0.14%) advanced.

Aurobindo Pharma added 1.14% after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray.

Stocks in Spotlight:

Jupiter Wagons shed 0.68%. The company said that its board has considered and approved the acquisition of Bonatrans India, which shall eventually become the subsidiary company upon completion of acquisition.

Deccan Gold Mines (DGML) jumped 5.81% after the company announced that its subsidiary Deccan Gold Tanzania has discovered a gold block in the Nzega-Tabora Greenstone belt, Tanzania.

GPT Healthcare rallied 5.75% after the company’s consolidated net profit jumped 37.37% to Rs 11.47 crore in Q3 FY24 as compared with Rs 8.35 crore in Q3 FY23. Revenue from operations increased 3.88% YoY to Rs 96.59 crore in the quarter ended 31 December 2023.

Global Markets:

Asian stocks advanced on Wednesday after US equities rose overnight and bonds also rallied as traders brace for the latest monetary policy decision from the Federal Reserve. Japanese markets are closed for a holiday.

Wall Street's three major indexes closed higher on Tuesday after shares in hotshot chipmaker Nvidia shook off early losses and investors looked ahead to the Federal Reserve's policy meeting conclusion on Wednesday for clues on interest rate policy.

Powered by Capital Market - Live News